Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
MIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq:ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Amy Chappell, M.D., FAAN, will be presenting preclinical in vivo data evaluating BAER-101 using the SynapCell’s Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of absence epilepsy at the American Epilepsy Society (AES) 2023 Annual Meeting in Orlando, FL on December 2, 2023.
Related news for (ATXI)
- Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
- Sidoti Events, LLC’s Virtual January Micro-Cap Conference
- Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
- Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds
- Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol